BRAFTOVI + MEKTOVI combination approved for advanced BRAF-mutant melanoma.
Singapore-based oncology-focused company targeting diseases that are both highly prevalent in Asia and that have orphan indications in the US and Europe.
To develop and commercialize a multi-gene panel for broad tumor profiling, leading to a next generation sequencing based companion diagnostic.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Array Technologies Inc manufacturers of ground-mounting systems used in solar energy projects. The company's product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers referred to as a single-axis tracker that move solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Its operations are in United States, Australia, and Rest of the World with United States deriving majority of the revenue.
| Website: | www.arraytechinc.com |
| Email: | investors@arraytechinc.com |
| Main Phone: | +1 505 881-7567 |
| Address: | 3901 Midway Place NE |
| State: | NM |
| City / Town: | Albuquerque |
| Country: | US |
| Postal Code: | 87109 |
| Exchange: | NSD |
| CEO: | Jim Fusaro |
| Employees: | 389 |
| NAICS: | Semiconductor and Related Device Manufacturing(334413) |
BRAFTOVI + MEKTOVI combination approved for advanced BRAF-mutant melanoma.
Singapore-based oncology-focused company targeting diseases that are both highly prevalent in Asia and that have orphan indications in the US and Europe.
To develop and commercialize a multi-gene panel for broad tumor profiling, leading to a next generation sequencing based companion diagnostic.
Median progression-free survival of 14.9 months using encorafenib and binimetinib together.
At Equities.com we’re interested in the disparity between performance and analyst proselytizing, which inspired us back in June to look at six specific biotech plays that had lost value on
Sometimes there are stocks that take a beating, but for whatever reason, the analysts won’t let them go. We decided to look at stocks that have had a rough go, but according to the analysts, are
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
